The global plasma therapy market comprises various types of platelet-rich plasma that are used by hospitals & clinics and several research institutions.

Rise in the number of orthopedic disorders associated with trauma and aging led to the increased demand for minimally-invasive therapies. This has further contributed to the increased demand for PRP in orthopedic, dermatology, nerve injury, cardiac muscle injury, and dental applications.

Download FREE Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=186196333

This market is driven by several factors such as prevalence of orthopedic disorders such as arthritis and increase in healthcare expenditure.

On the other hand, stringent regulatory policies and lack of awareness about platelet-rich therapy are factors restraining the growth of the expected to grow from USD 135.6 Million in 2016 to USD 297.6 Million by 2021, at a CAGR of 14.0% during the forecast period.

Based on end user, the plasma therapy market is segmented into hospitals & clinics and research institutions. The hospitals & clinics segment is estimated to account for the largest share of the global market in 2016. Rise in healthcare spending has resulted in the increasing use of PRP in hospitals & clinics.

North America led the global market, followed by Europe, Asia-Pacific, and rest of the world (RoW).

Major players operating in this market include BioLife Plasma Services (U.S.), Cambryn Biologics LLC (U.S.), Biotest (Germany), CSL Ltd. (Australia), Grifols International S.A. (Spain), Kedrion S.p.A. (Italy), LFB (France), Bio Products Laboratory Ltd. (U.K.), China Biologic Products, Inc. (China), and Octapharma (Switzerland).

To Know More @ https://www.marketsandmarkets.com/Market-Reports/plasma-therapy-market-186196333.html